资讯

Superluminal Medicines Raises $60M Series B to Advance Obesity Drug

unite.ai·2026/9/3 10:15:01🔗 原文

📋总体概括

Superluminal Medicines, a Boston biotechnology company applying AI and machine learning to drug discovery, announced on September 3, 2026 the closing of an oversubscribed $60 million Series B financin

⚡关键信息

▸Superluminal Medicines, a Boston biotechnology company apply

📰 相关资讯（与本文相关的其他资讯）

资讯NVIDIA Signs Definitive Agreement to Acquire Hugging Face for $12.9B🔥9.0

unite.ai·2026/9/3

资讯手机涨价潮调查：存储芯片重塑行业格局🔥9.0

财联社深度·2026/9/3

资讯全都漏光！苹果2026年秋季新品发布会前瞻解析🔥9.0

驱动之家·2026/9/3

资讯博通财报电话会实录：AI收入未来两年连续翻番，“实际需求甚至更高”🔥9.0

财联社深度·2026/9/3

本文由本站自动聚合，以下为原始来源：前往 unite.ai 阅读全文 →

← 返回资讯流